3 AI Drug Discovery Stocks Retail Investors Are Watching Now

AI is no longer just a tech story; it is starting to reshape how drugs are found, labs are run and scientific ideas move from whiteboard to real-world treatments. That shift could change which stocks benefit from faster research, leaner workforces and new security needs as AI spreads into critical systems. This article highlights three AI enabled drug discovery and R&D platforms from the screener that appear most exposed to the latest Anthropic driven headlines.

The three stocks highlighted below are just a starter set from the screen, while the full process surfaced 31 more AI linked drug discovery and R&D platforms with equally compelling stories that are not covered in this article. To go wider and identify your own highest conviction ideas, head straight into the AI-Enabled Drug Discovery & Scientific R&D Platforms screener.

Insmed (INSM)

Insmed taps AI mainly behind the scenes, using advanced computational tools to support research into serious and rare diseases rather than selling AI as a product. That mix of tech-enabled science and late stage respiratory drugs is what makes the story interesting here.

Insmed develops and commercializes therapies for serious and rare diseases, generating about US$1.1b from its rare disease portfolio, and carries a market value around US$21.7b.

"The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. Potential label expansion for ARIKAYCE based on the Phase III ENCORE trial readout in Q1 2026 could address a larger patient population, leading to a substantial increase in revenue."

What happens if a single assumption about how quickly prescribers adopt this AI-supported respiratory portfolio shifts even a little?

If that adoption curve is what matters most for you, read the full narrative for Insmed to see how Insmed’s AI work could accelerate or stall that thesis.

Cabot (CBT)

Cabot brings the AI-Enabled Drug Discovery and Scientific R&D Platforms theme in through the backdoor, as a specialty chemicals group whose advanced carbons, silicas and aerogels feed into the materials and lab infrastructure that AI-heavy research increasingly leans on.

Cabot Corporation produces specialty chemicals and performance materials, with Reinforcement Materials contributing about US$2.2b in revenue and Performance Chemicals around US$1.3b, plus smaller unallocated activities. The Boston based business has a market value of roughly US$3.9b.

"Rising energy and transportation costs and potential further volatility in oil linked feedstocks, even with pass-through mechanisms and recent price increases of up to 20% in Specialty Carbons and Specialty Compounds, could outpace Cabot's ability to reprice contracts and weigh on segment gross profit per ton and overall net margins."

What investors really need to watch is how one less visible pressure point either quietly protects Cabot’s earning power or steadily erodes it.

If that quiet squeeze on profitability is what you care about most, read the full narrative for Cabot to see whether Cabot’s pricing power is quietly compounding opportunity.

Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies sits closest to the AI enabled drug discovery theme in this screen, using machine learning on immune system data to fuel both diagnostics and potential therapy development while generating about US$252 million from MRD testing, US$56 million from Immune Medicine and carrying a roughly US$4.1b market value.

Adaptive Biotechnologies turns its immune medicine platform into a data engine for drug discovery and clinical decision making, so what matters for investors is not just more sequencing capacity but how deeply that data gets stitched into everyday workflows.

"Accelerating integration of clonoSEQ into electronic medical records (EMRs) across both academic and community settings, as well as the major rollout with Flatiron's OncoEMR and expansion through partnerships like NeoGenomics, streamlines ordering and supports recurring test usage. This is expected to drive strong multi-year clinical volume growth and recurring revenue."

What happens to Adaptive Biotechnologies’ earnings power if one less visible economic assumption about that AI ready testing demand curve shifts even slightly.

That quiet shift in testing behavior is where the real leverage sits, and the full narrative for Adaptive Biotechnologies lays out how Adaptive Biotechnologies could turn that into accelerating immune data economics.

Seeking Alternatives Before Momentum Flies Past

Fresh opportunities move fast. Some tickers are already building breakout momentum while others stay under the radar for now. Do your homework before the crowd catches up and act now.

• Consider targeting reliable cash flow while the market hesitates around income names by scanning the 8 dividend fortresses that focus on durable payouts and defensive balance sheets.
• Consider ways to participate in early AI momentum without chasing headlines by filtering for 38 profitable AI stocks that aren't just burning cash that already back their stories with earnings and disciplined spending.
• Evaluate positioning ahead of potential infrastructure upgrade activity by reviewing 41 power grid technology and infrastructure stocks that may benefit from grid modernization and electrification themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com